Keyword Index

S99

Keyword Index

Acetylcholine; S17 (P.1.19), S20 (P.1.23), S42 (P.2.07), S52 (P.2.20), S87 (P.4.03), S92 (P.4.10) Adolescence; S25 (P.1.29) Aggression: – basic; S78 (P.3.19) – clinical; S73 (P.3.14) Alcoholism; S58 (P.2.27), S59 (P.2.28), S65 (P.3.04) Alzheimer’s disease, behaviour, cognition; S85 (S.4.02) Alzheimer’s disease: – basic; S85 (P.4.01), S86 (P.4.02), S87 (P.4.03), S88 (P.4.04), S89 (P.4.06), S91 (P.4.08), S92 (P.4.09) Amino acids; S60 (P.2.30), S67 (P.3.06) Anhedonia; S44 (P.2.09) Animal models; S2 (P.1.01), S5 (P.1.04), S11 (P.1.12), S14 (P.1.16), S16 (P.1.18), S17 (P.1.20), S19 (P.1.22), S22 (P.1.26), S23 (P.1.27), S36 (S.2.02), S38 (P.2.02), S42 (P.2.07), S44 (P.2.09), S45 (P.2.11), S48 (P.2.14), S51 (P.2.18), S55 (P.2.23), S90 (P.4.07), S92 (P.4.10), S93 (P.4.11) Antidepressants: – basic; S3 (P.1.02), S4 (P.1.03), S9 (P.1.09), S19 (P.1.22), S29 (P.1.35), S40 (P.2.04) – clinical; S64 (P.3.03), S72 (P.3.12), S75 (P.3.16) Anxiety; S10 (P.1.11), S48 (P.2.15), S53 (P.2.21) Anxiety disorders; S22 (P.1.26) Behavioural pharmacology; S25 (P.1.29), S29 (P.1.35), S35 (S.2.01), S37 (P.2.01), S38 (P.2.02), S39 (P.2.03), S41 (P.2.06), S46 (P.2.12), S47 (P.2.13), S49 (P.2.16), S50 (P.2.17), S52 (P.2.19), S54 (P.2.22), S59 (P.2.28), S60 (P.2.29, P.2.30), S78 (P.3.19), S80 (P.3.21), S90 (P.4.07), S93 (P.4.11) Benzodiazepines; S8 (P.1.08), S57 (P.2.26), S89 (P.4.06) Biological markers; S13 (P.1.15), S14 (P.1.16), S73 (P.3.13) Biological rhythms; S12 (P.1.13)

Bipolar disorders; S13 (P.1.15), S63 (P.3.01), S68 (P.3.07) Cannabinoid system; S52 (P.2.19) Cannabinoids; S25 (P.1.29) Cell culture; S6 (P.1.06), S11 (P.1.12), S88 (P.4.05), S89 (P.4.06) Cigarettes; S77 (P.3.18) Cognitive enhancing drugs; S69 (P.3.08), S90 (P.4.07), S92 (P.4.10) Cognitive functioning; S77 (P.3.18) Depression: – basic; S1 (S.1.01), S4 (P.1.03), S12 (P.1.13), S17 (P.1.20), S23 (P.1.27), S28 (P.1.33), S35 (S.2.01), S39 (P.2.03), S40 (P.2.04), S43 (P.2.08) – clinical; S9 (P.1.10), S64 (P.3.03), S68 (P.3.07), S70 (P.3.10), S74 (P.3.15), S75 (P.3.16) Dopamine; S5 (P.1.05), S6 (P.1.06), S9 (P.1.09), S15 (P.1.17), S20 (P.1.23), S21 (P.1.25), S30 (P.1.36), S31 (P.1.37), S40 (P.2.05), S47 (P.2.13), S50 (P.2.17), S52 (P.2.20), S56 (P.2.24), S69 (P.3.08) Drug dependence and abuse: – basic; S5 (P.1.05), S7 (P.1.07), S35 (S.2.01), S37 (P.2.01), S41 (P.2.06), S49 (P.2.16), S50 (P.2.17), S51 (P.2.18), S54 (P.2.22), S55 (P.2.23), S56 (P.2.24), S78 (P.3.19) – clinical; S30 (P.1.36), S65 (P.3.04), S66 (P.3.05), S69 (P.3.09), S77 (P.3.18) Drug development; S87 (P.4.03) Drug monitoring; S74 (P.3.15) Drugs for dementia; S86 (P.4.02), S88 (P.4.05), S93 (P.4.11) Eating disorders; S13 (P.1.14) Emotional Processing; S64 (P.3.03) Excitatory neurotransmitters; S60 (P.2.29) GABAA receptor; S8 (P.1.08) Gender differerences; S54 (P.2.22) Gene expression; S2 (P.1.01), S5 (P.1.04), S13 (P.1.14), S18 (P.1.21), S36 (S.2.02)

Genetics/Molecular genetics; S9 (P.1.10), S13 (P.1.15), S21 (P.1.24), S31 (P.1.37), S36 (S.2.02), S43 (P.2.08), S63 (P.3.01), S70 (P.3.10), S85 (P.4.01) Glutamate; S2 (P.1.01), S3 (P.1.02), S16 (P.1.18), S26 (P.1.31), S32 (P.1.38), S56 (P.2.24), S70 (P.3.10) Immediate early genes; S5 (P.1.05), S10 (P.1.11), S15 (P.1.17), S27 (P.1.32), S53 (P.2.21) Inhibitory neurotransmitters; S17 (P.1.19) Ion channels; S63 (P.3.01) Lipopolysaccharide; S44 (P.2.10) Memory and cognitive disorders; S41 (P.2.06), S45 (P.2.11), S57 (P.2.25), S64 (P.3.02), S65 (P.3.04), S69 (P.3.09), S74 (P.3.15), S80 (P.3.21) Methodology; S67 (P.3.06) Molecular neurobiology; S7 (P.1.07), S21 (P.1.25), S24 (P.1.28), S88 (P.4.04), S92 (P.4.09) Multi-day behavioural recordings; S48 (P.2.15) Natural products; S57 (P.2.25) Neuroanatomy; S22 (P.1.26), S53 (P.2.21), S79 (P.3.20) Neuroendocrinology; S12 (P.1.13), S23 (P.1.27), S26 (P.1.31), S27 (P.1.32) Neuroimaging: – functional; S64 (P.3.02), S69 (P.3.08), S71 (P.3.11), S72 (P.3.12), S76 (P.3.17), S80 (P.3.21, P.3.22), S81 (P.3.23) – structural; S28 (P.1.34), S81 (P.3.23) Neuroimmunology; S18 (P.1.21), S25 (P.1.30), S57 (P.2.25) Neuroleptics and antipsychotics: – basic; S48 (P.2.14) – clinica; S68 (P.3.07), S73 (P.3.13, P.3.14) Neuropeptides; S1 (S.1.01), S58 (P.2.27) Neurophysiology: – basic; S79 (P.3.20) Neuroprotection; S11 (P.1.12), S86 (P.4.02), S88 (P.4.05)

S100

Neuropsychology; S43 (P.2.08) Neurosteroids; S8 (P.1.08), S58 (P.2.27) New research; S45 (P.2.11), S69 (P.3.09) Noradrenaline; S25 (P.1.30), S59 (P.2.28)

Opiates; S40 (P.2.05), S46 (P.2.12), S49 (P.2.16) Other dementia; S85 (P.4.01) Other neurotransmitters; S37 (P.2.01)

Panic disorders; S57 (P.2.26) Parkinson’s Disease; S52 (P.2.20) Personality disorders; S82 (P.3.24) Pharmacogenetics; S75 (P.3.16) Proteomics; S19 (P.1.22) Psychoneuroendocrinology; S13 (P.1.14), S28 (P.1.34), S71 (P.3.11) Psychoneuroimmunology; S14 (P.1.16)

Keyword Index Receptors; S21 (P.1.25), S25 (P.1.30), S30 (P.1.36), S32 (P.1.38), S71 (P.3.11), S80 (P.3.22), S82 (P.3.24) Schizophrenia: – basic; S5 (P.1.04), S6 (P.1.06), S15 (P.1.17), S18 (P.1.21), S20 (P.1.23), S31 (P.1.37), S32 (P.1.38), S38 (P.2.02), S42 (P.2.07), S48 (P.2.14), S52 (P.2.19), S76 (P.3.17), S79 (P.3.20) – clinical; S67 (P.3.06), S73 (P.3.13, P.3.14), S76 (P.3.17) Sensitization/Tolerance; S55 (P.2.23) Serotonin; S1 (S.1.01), S9 (P.1.09), S17 (P.1.20), S21 (P.1.24), S28 (P.1.34), S39 (P.2.03), S47 (P.2.13), S51 (P.2.18), S60 (P.2.30), S64 (P.3.02), S66 (P.3.05), S72 (P.3.12), S80 (P.3.22), S81 (P.3.23), S82 (P.3.24)

Signal transduction; S3 (P.1.02), S4 (P.1.03), S17 (P.1.19), S24 (P.1.28), S26 (P.1.31), S91 (P.4.08) Sleep disorders; S66 (P.3.05) Startle; S44 (P.2.09) Stress; S7 (P.1.07), S10 (P.1.11), S16 (P.1.18), S21 (P.1.24), S24 (P.1.28), S27 (P.1.32), S28 (P.1.33), S29 (P.1.35), S44 (P.2.10), S46 (P.2.12) Transgenic models; S40 (P.2.04, P.2.05), S48 (P.2.15), S57 (P.2.26), S60 (P.2.29), S88 (P.4.04), S91 (P.4.08), S92 (P.4.09) Tryptophan hydroxylase 2; S44 (P.2.10) Vasopressin; S28 (P.1.33) Whole Genome Association (WGA); S9 (P.1.10)